---

The sentence everyone reads past

Every peptide sold in this market carries some version of the same line: for laboratory and research use only, not for human or animal consumption. Most people scroll past it. A fair number assume it is legal boilerplate - something a lawyer told the company to add, meaning roughly nothing.

We understand why it reads that way. Plenty of sellers treat it exactly that way, which is the problem.

The line is not decoration. It describes what the material is and what it is for, and that description carries obligations for us. This post explains what those obligations actually are, why we hold to them even when it costs us a sale, and how to tell whether a supplier is doing the same thing or just wearing the costume.

Intended use is a legal concept, not a preference

Start with how federal law decides what a product is.

Under Section 201(g) of the Federal Food, Drug, and Cosmetic Act, "drug" is defined by purpose. Anything intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease falls under FDA's authority as a drug - regardless of what the substance is, what it is called, or how it is packaged.

That word intended is doing enormous work. FDA's intended use regulations, at 21 CFR 201.128 for drugs and 21 CFR 801.4 for devices, were finalized in their current form in August 2021. They describe intended use as the objective intent of the people responsible for the product's labeling. Intent can be shown by what those people say, and it can equally be shown by the circumstances surrounding how the article is distributed.

Read that again, because it is the whole ballgame. A statement is evidence of intent. So is conduct. So is context. A disclaimer is one piece of evidence sitting alongside every other piece, and it does not outrank them.

Which means a seller cannot label a product for research, then market it for human use, and rely on the label to settle the question. The label and the marketing are both evidence, and if they contradict each other, the contradiction is the finding.

What FDA has actually said about the label itself

The most direct guidance on the RUO designation is FDA's November 2013 document on the distribution of in-vitro diagnostic products labeled for research use only or investigational use only. Two things about it are worth knowing.

First, that guidance addresses IVD products specifically - reagents, instruments and systems. Research chemicals are a different category, and anyone telling you the 2013 guidance is a formal FDA blessing for research-peptide sales is overstating it. There is no separate FDA regime that carves out research chemicals from drug law. They sit under the same intended-use analysis as everything else.

Second, and more usefully: the guidance is explicit that the label alone is not sufficient. A manufacturer's other conduct matters. Providing instructions, protocols or support that would enable clinical use undermines the research-use claim regardless of what the labeling says.

That second point is the operative principle for a peptide supplier, even though the guidance was written for a different product category. If you supply the material and the instructions for using it on a person, you have answered the intended-use question yourself.

What this means for how we operate

We get asked constantly. How much. How often. What to mix it with. What to expect. The questions are usually polite and completely sincere, and we understand the frustration when we decline.

We decline because answering would change what we are. A supplier that provides human-use guidance alongside the material is not a research supplier with a cautious disclaimer - it is a seller of unapproved drugs with a disclaimer that no longer describes anything true.

So, concretely, here is what we will and will not do.

We will: tell you where a compound was synthesized, which lab produced the certificate of analysis, what analytical methods were run, what the purity figure means and whether it is HPLC purity or net peptide content, how the material should be stored and shipped, and what the published research literature reports about the compound in the systems where it has been studied.

We will not: recommend quantities for a person, describe administration, discuss expected effects in humans, suggest combinations, or characterize any product as suitable for any human or veterinary purpose. Our policy is that this applies across every channel we operate.

Laboratory handling, storage and reconstitution references for research work are maintained separately at peptideorders.com.

What RUO does not mean

Four misreadings come up often enough to name directly.

It does not mean unregulated. Research materials are not outside FDA's reach. They are inside it, classified by intended use like everything else.

It does not mean lower quality. Research-grade is a use designation, not a purity tier. A research compound from a WHO/GMP facility with full analytical documentation is a better-characterized material than a compounded product from a pharmacy with thin quality systems. The label says nothing about the chemistry.

It does not resolve a contradiction elsewhere on the site. Where a disclaimer sits at the bottom of a page and the marketing above it points somewhere else, the framework described earlier does not treat the disclaimer as the answer. Both are evidence, and they are weighed together.

It does not mean the seller has been vetted. Anyone can type the words. The label is a claim about intent, not a certification anybody issued.

Why 2026 made this more important, not less

This year produced the loudest regulatory news the peptide category has ever had. In July, an FDA advisory committee recommended six peptides for the 503A Bulks List. Coverage was everywhere. Interpretation was mostly wrong.

The claim that spread fastest was that peptides had been legalized or approved. They were not. Advisory votes are non-binding, no final determination has issued, and formal listing requires notice-and-comment rulemaking that has not concluded. We wrote about where the process actually stands and which compounds FDA reviews next.

Here is the part that matters for this post. Even in the world where every one of those six is eventually added to the list, that pathway runs through a licensed compounding pharmacy filling a prescription written by a clinician for a named patient. It does not run through an online vendor, and it will not run through us. A research supplier does not become a pharmacy because the regulatory weather improved.

Meanwhile, enforcement attention has moved in the other direction. Regulators have signaled that sellers using research labeling as cover while marketing to consumers are exposed - and that websites, social accounts and advertising suggesting human consumption are what draws that exposure. The label does not protect a seller whose own marketing contradicts it. That has always been true. It is simply being said out loud more often now.

So the honest summary of 2026 is this: the conversation got louder, the scrutiny got sharper, and the line stayed exactly where it was.

How to evaluate any supplier on this

Four questions, and you can answer them yourself in about ten minutes on a supplier's own website.

• Does the marketing contradict the disclaimer? Look at the social accounts, not the footer. Before-and-after images, testimonials describing results in people, or influencer content demonstrating injection are the tell.
• Will they answer chemistry questions in specific terms - synthesis location, testing lab, methods, purity basis?
• Will they refuse a human-use question, plainly, without hedging or a private-message workaround?
• Does anything on the site imply that the 2026 regulatory news changed what you can legally do with the material?

A supplier that passes all four is behaving consistently. A supplier that fails the first one has already told you what the disclaimer is worth.

Frequently asked questions

What determines how a research peptide is classified?

Intended use, as described above. Under Section 201(g) of the FD&C Act a product is classified by the purpose it is intended for, and the intended-use regulations treat both statements and the circumstances of distribution as evidence of that purpose. We can't speak to any individual's situation - that is a question for an attorney.

Does "research use only" mean the peptide is low quality?

No. It is a designation of intended use, not a grade of material. Purity and characterization are established by analytical testing and documentation, not by the use label.

Did the July 2026 FDA advisory votes make peptides legal for personal use?

No. The votes were non-binding recommendations, no substance has been formally listed, and none of it changes the status of material sold for research.

Why won't you tell me how to use a product I bought?

Because supplying human-use instructions alongside the material would make the research designation untrue. It is not a customer service failure. It is the designation working as intended.

What is the difference between RUO and a compounded prescription?

A compounded preparation is made by a licensed pharmacy for a specific patient with a prescription, under section 503A. Research material is supplied for laboratory work and is not part of that pathway.

Where we stand

BioPure Peptides manufactures in the United States in a WHO/GMP and ISO 9001 certified facility and tests to greater than 99% purity. We will discuss specifications, documentation, methods and sourcing at whatever depth you want, and our team in Chandler, Arizona can be reached at (888) 745-1505 or through our contact page.

We will not discuss what to do with the material after it leaves us. If that is what you need from a supplier, we are not the right one - and we would gently suggest that a supplier willing to provide it is telling you something about how seriously it takes the rest of its claims.

All products sold by BioPure Peptides are intended strictly for in-vitro laboratory and research use only. They are not for human or animal consumption. These statements have not been evaluated by the U.S. Food and Drug Administration, and these products are not intended to diagnose, treat, cure, or prevent any disease. This article is general information about a regulatory framework and is not legal advice.